| Aug 2 |
Bristol ends licensing agreement with Agenus on TIGIT bispecific antibody
|
| Aug 1 |
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
| Jul 31 |
Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
|
| Jul 26 |
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
| Jul 26 |
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
|
| Jul 24 |
Agenus: Novel Drugs That Just Are Not Novel
|
| Jul 19 |
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
|
| Jul 19 |
Agenus downgraded at Baird after FDA feedback on cancer drug
|
| Jul 19 |
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
|
| Jul 18 |
Agenus stock plunges 60% on FDA feedback on BOT/BAL therapy
|
